Infliximab trough levels and anti-drug antibodies after induction predict long-term clinical remission in infliximab-treated patients with inflammatory bowel disease

被引：0
|
作者：
Bodini, G. [1 ]
Del Nero, L. [1 ]
Giannini, E. G. [1 ]
Tolone, S. [2 ]
De Bortoli, N. [3 ]
Anjali, J. [4 ]
Baldissarro, I. [1 ]
Savarino, V. [1 ]
Savarino, E. [5 ]
机构：
[1] Univ Genoa, Dept Internal Med, I-16126 Genoa, Italy
[2] Univ Naples 2, Dept Surg, Naples, Italy
[3] Univ Pisa, Dept Internal Med, Gastroenterol Unit, Pisa, Italy
[4] Prometheus Labs, Dept Res & Dev, San Diego, CA USA
[5] Univ Padua, Dept Surg Oncol & Gastroenterol, Gastroenterol Unit, Padua, Italy
来源：
JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P607
引用
收藏
页码：S408 / S409
页数：2
相关论文
共 50 条
  • [41] Long-Term Clinical Outcome After Discontinuation of Infliximab Therapy in Patients with Inflammatory Bowel Disease Who Responded to Induction Therapy
    Lee, Ji Min
    Lee, Kang-Moon
    Kim, Yoon Jae
    Yoon, Hyuk
    INFLAMMATORY BOWEL DISEASES, 2017, 23 : S39 - S39
  • [42] A MODEL UTILIZING WEEK 6 INFLIXIMAB TROUGH LEVELS PREDICTS ONE YEAR PERSISTENT REMISSION IN INFLIXIMAB-TREATED PEDIATRIC IBD PATIENTS
    Singh, Namita
    Arora, Yogesh
    Yakub, Jasmine
    Cook-Wiens, Galen
    Hester, Kelly
    Kondragunta, Venkateswarlu
    Jain, Anjali
    Rabizadeh, Shervin
    Dubinsky, Marla
    GASTROENTEROLOGY, 2018, 154 (06) : S825 - S825
  • [43] Discriminating between response types in infliximab-treated patients with Crohn's disease: Sensitivity and specificity of combined assessment of infliximab trough levels and antidrug antibodies
    Steenholdt, Casper
    Bendtzen, Klaus
    Thomsen, Ole Ostergaard
    Brynskov, Jorn
    Ainsworth, Mark
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2010, 45 : 59 - 59
  • [44] Clinical correlations of infliximab trough levels and antibodies to infliximab in Korean patients with Crohn's disease
    Oh, E. H.
    Ko, D. -H.
    Seo, H.
    Chang, K.
    Kim, G. -U.
    Song, E. M.
    Seo, M.
    Lee, H. -S.
    Hwang, S. W.
    Yang, D. -H.
    Ye, B. D.
    Byeon, J. -S.
    Myung, S. -J.
    Yang, S. -K.
    Park, S. H.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S283 - S284
  • [45] Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab
    Orfanoudaki, Eleni
    Gazouli, Maria
    Foteinogiannopoulou, Kalliopi
    Theodoraki, Eirini
    Legaki, Evangelia
    Romanos, Ioannis
    Mouzas, Ioannis
    Koutroubakis, Ioannis E.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (02) : 187 - 191
  • [46] Infliximab trough levels during maintenance are predictive for infliximab efficacy in paediatric patients with inflammatory bowel disease
    van Hoeve, K.
    Hoffman, I.
    Dreesen, E.
    Ferrante, M.
    Gils, A.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S180 - S181
  • [47] Early Trough Levels and Antibodies Predict Safety and Success of Restarting Infliximab After Long Drug Holiday
    Baen, Filip J.
    Drobne, David
    Ballet, Vera
    Cleynen, Isabelle
    Compemolle, Griet
    Riugeens, Paul J.
    Van Assche, Gen A.
    Gils, Ann
    Venneire, Severine
    GASTROENTEROLOGY, 2011, 140 (05) : S62 - S62
  • [48] Trough Levels and Antidrug Antibodies Predict Safety and Success of Restarting Infliximab After a Long Drug Holiday
    Baert, Filip J.
    Drobne, David
    Ballet, Vera
    Gils, Ann
    Casteele, Niels Vande
    Hauenstein, Scott
    Singh, Sharat
    Lockton, Steven
    Rutgeerts, Paul J.
    Vermeire, Severine
    GASTROENTEROLOGY, 2013, 144 (05) : S91 - S92
  • [49] Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission
    Guerrero Puente, Lourdes
    Iglesias Flores, Eva
    Manuel Benitez, Jose
    Medina Medina, Rosario
    Salgueiro Rodriguez, Isabel
    Aguilar Melero, Patricia
    Cardenas Aranzana, Manuel Jesus
    Gonzalez Fernandez, Rafael
    Manzanares Martin, Barbara
    Garcia-Sanchez, Valle
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2017, 40 (09): : 595 - 604
  • [50] Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays
    Al-Bawardy, Badr
    Jenkins, Sarah M.
    Snyder, Melissa R.
    Frinack, Jody L.
    Ladwig, Paula M.
    Loftus Jr, Edward V.
    Willrich, Maria Alice V.
    CLINICAL BIOCHEMISTRY, 2023, 119
12345